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Despite the fact that a variety of therapeutic strategies for uro-
logical malignancies have achieved a substantial improvement in
prognoses, the renal cell carcinoma (RCC) largely remains an
exception, and curative treatment of progressive RCC remains
extremely difficult. It is well known that RCC displays a unique
biological profile (Ritchie et al, 1987), e.g. long dormancy of
metastases and spontaneous regression of metastatic disease,
suggesting that RCC patients can raise abortive immune responses
against as yet unknown tumour components. Investigations of RCC
patient’s immune status have also indicated that this influences the
biological behaviour of the tumour (De Riese et al, 1991). Since
RCC is relatively resistant to conventional treatment, such as
radiation and chemotherapy, immunotherapy seems to be the most
promising therapeutic approach. Although biological response
modifiers have shown a substantial efficacy in selected cases, the
response rates hardly exceed 30% and most patients cannot be
cured (Wirth, 1993). Clearly, tumour-specific immunotherapy
would be advantageous but unequivocal evidence for the existence
of unique tumour-specific antigens in human malignancies is still
lacking. A murine monoclonal antibody G250 (mAbG250) raised
against human RCC is, however, known to react with a large
proportion of RCCs, whereas the reactivity with normal tissues is
restricted to cells of gastric mucosa and large bile ducts (Oosterwijk
et al, 1986). Taking advantage of the specific reactivity with RCC,
we have shown that treatment of mice bearing RCC xenografts
with mAbG250 results in significant anti-tumour effects (Van Dijk
et al, 1995). We also have shown that vaccination with the internal
image anti-idiotype antibodies against mAbG250 results in the
destruction of established RCC tumours, suggesting potential
benefit with surrogate antigens for active specific immunotherapy
(Uemura et al, 1994a, 1994b). Clinical trials with 131I-mAbG250 as
well as 131I-chimeric mAbG250 (ch-mAbG250) for radiodiagnosis
have shown safety and tumour specificity (Oosterwijk et al, 1993;
Steffens et al, 1997). These results suggest that this antigen can be
useful as a therapeutic and diagnostic target.
Recently, the G250 antigen was sequenced and was revealed by
database analysis to be homologous to the MN/CA IX antigen, a
tumour-associated antigen originally identified in HeLa cells
(Pastorek et al, 1994; Oosterwijk et al, 1996). This antigen
(MN/CA IX/G250) is a plasma membrane glycoprotein with an
apparent molecular weight of 54/58 kDa, detectable in several
types of malignancies; e.g. cervical and ovarian cancer (Liao et al,
1996), renal cancer (Oosterwijk et al, 1986), colorectal cancer
(Saarnio et al, 1998), oesophageal cancer (Turner et al, 1997),
bladder cancer (Uemura et al, 1996), but not in the normal tissues
except alimentary tract, suggesting a possible role in oncogenesis.
Sequential analysis has demonstrated that this gene (MN/
CA9/G250) is a novel member of the carbonic anhydrase (CA)
family and MN/CA IX/G250 is considered to be the only tumour-
associated CA isoenzyme. Although the functional significance of
MN/CA IX/G250 in oncogenesis remains unclear, MN/CA
IX/G250 can induce malignant phenotype in murine NIH 3T3
fibroblasts, suggesting that MN/CA IX/G250 plays a role in
control of cell proliferation and transformation (Pastorek et al,
1994). In addition, recent reports confirmed that MN/CA IX/G250
may be useful as a potentially important biomarker for cervical
carcinomas (Liao et al, 1994; Brewer et al, 1996) and RCC (Liao
et al, 1997; McKiernan et al, 1997). However, MN/CA IX/G250
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(Pastoreková et al, 1997). A sequential study of stomach cDNA
showed no difference between normal and tumour tissue-derived
cDNAs, indicating that MN/CA9/G250-associated oncogenesis
may depend on the gene expression without mutations
(Pastoreková et al, 1997). Moreover, a recent investigation by
Ivanov et al (1998) focused on the genes involved in von
Hippel–Lindau (VHL)-mediated carcinogenesis, and indicated
down-regulation of MN/CA9/G250 gene expression in RCC cell
lines by wild-type VHL transgenes (Ivanov et al, 1998).
Thus, MN/CA9/G250 gene may be related to carcinogenesis in
RCC and MN/CA IX/G250 antigen may be a tumour-associated
biomaker in RCC. Although the G250 antigen has been cloned and
found to be homologous to MN/CA9, a precise correlation between
MN/CA9 gene and G250 antigen expression has not been shown.
Therefore, we evaluated MN/G250 expression in a large number
of RCC extensively by both immunohistochemistry and RT-PCR
assay, and correlated the data with clinicopathological parameters.
Moreover, since the haematogenous metastasis of RCC is well
established and there is no reliable serological marker as a prog-
nostic indicator, we applied RT-PCR technology for molecular
detection of circulating MN/CA9/G250-positive cells in blood
samples from RCC patients.
MATERIALS AND METHODS
Cells
Human RCC SK-RC series cell lines, reactive and non-reactive
with mAbG250, were obtained from the Sloan-Kettering Institute,
New York. YCR-1 was kindly supplied by Professor T Shuin of
the Department of Urology, Kochi Medical College. Cells were
cultured in RPMI-1640 medium supplemented with L-glutamine
and 10% fetal bovine serum.
Specimens
RCC and corresponding normal kidney tissues were obtained by
radical operations in our department. All specimens were certainly
kept under RNAase-free conditions immediately after nephrec-
tomy, and small pieces of tumour or normal kidney tissue were
frozen in liquid nitrogen and stored at –80°C. The remainder of
each kidney was submitted for pathological examination by the
central pathologist (KI) at this institute.
Monoclonal antibody
A murine monoclonal antibody, mAbG250 (IgG1, IgG2a), which
recognizes the MN/CA IX/G250 antigen, was used for immuno-
histochemical staining and mixed haemadsorption assays (MHA).
The isolation and characterization of mAbG250 has been
described elsewhere (Oosterwijk et al, 1986).
Immunohistochemistry of RCC specimens
Immunohistochemistry of frozen tissues was carried out as
described previously (Uemura et al, 1995). Briefly, 4–5-micron-
thick cryostat sections were airdried for 1 h and fixed in
acetone/methanol for 10 min at room temperature. After washing
in phosphate-buffered saline (PBS), tissue sections were incubated
with mAbG250 for 1 h at room temperature. After a three further
washes with PBS, the tissue sections were incubated with goat
anti-mouse IgG conjugated to horseradish peroxidase, preincu-
bated with 10% normal human serum. The tissue sections were
developed with 3-3¢-diaminobenzidine and 0.01% hydrogen
peroxide for 10 min at room temperature. After washing with tap
water, the slides were counterstained with haematoxylin, and
mounted with Permount.
Mixed haemadsorption assay
RCC cell lines were examined for MN/CA IX/G250 antigen
expression on the cell surface by MHA. Briefly, the cells cultured
in 60-well plates overnight were incubated with appropriately
diluted mAbG250 for 60 min at room temperature, and subse-
quently with indicator sheep red blood cells (SRBC) treated with
mouse anti-SRBC and goat anti-mouse IgG antibody for 60 min at
room temperature. The reaction was determined as positive when
over 25% of the target cells formed rosettes.
RT-PCR analysis
Peripheral blood lymphocytes separated by centrifugation using
Ficoll-Conray (IBL, Gunma, Japan), tissues and cell lines were
used for preparation of total RNAs by homogenization in guani-
dium thiocyanate and centrifugation through caesium chloride.
Total RNAs were reverse transcribed with SuperScript RNAase H
reverse transcriptase (Gibco-BRL), using random primers. The
resulting cDNA fragments were then amplified by PCR, using
combined sense and anti-sense degenerate primers (sense primer;
5¢-ACTGCTGCTTCTGATGCCTGT-3¢, 126–146 nt, anti-sense;
5¢-AGTTCTGGGAGCGGCGGGA-3¢, 620–602 nt). The amplifi-
cation was achieved with 30 cycles, each consisting of denatura-
tion (95°C, 2 min), annealing (68°C 2 min), and extension (72°C,
1 min). The PCR products from several tissue RNAs were 495 bp
in length. For blood samples, to obtain a higher sensitivity of the
RT-PCR assay, PCR Southern blots were carried out. Briefly, PCR
products were electrophoresed in 1.5% agarose gels and trans-
ferred to nitrocellulose filters. The cDNA probe (167–447 nt) was
hybridized with filters at 42°C in the presence of 40% formamide,
and the filters were finally washed with 0.2 ´ standard saline
citrate, 0.1% sodium dodecyl sulphate at 60°C. The size of the
DNA was determined by comparison with lambda phage DNA
fragments digested with HindIII.
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Figure 1 MN/CA9 assessed by RT-PCR analysis in RCC patients. Case
numbers 1–5 (clear cell or granular cell type, grade 1–2 RCCs) demonstrate
clear expression of MN/CA9 mRNA whereas case number 6 (spindle cell
type, grade 3 RCC) is negative; like all the corresponding normal kidney
tissues. Representative results are shownRT-PCR assay sensitivity for detection of circulating
MN/CA9/G250-positive cells
To determine the sensitivity of the RT-PCR assay for detection
of circulating MN/CA9/G250-expressing cells, SKRC-44 (MN/
CA9/G250-positive cell line) cells were serially diluted into 10 ml
whole blood obtained from a 36-year-old healthy male volunteer
(MN/CA9/G250-negative blood). Briefly, a single cell suspension
of SKRC-44 was prepared in PBS and serial dilutions were carried
out. Different dilutions were added to 10-ml aliquots of normal
blood samples, to give concentrations of 0, 100, 101, 102, 103, 104,
105, 106 cells per 1 ml whole blood. For lymphocyte separation,
the blood samples were centrifuged using Ficoll–Conray. Total
RNA was extracted from the cell pellets and RT-PCR analysis was
performed as described above.
Statistical analysis
Correlations between MN/CA IX/G250 expression and clinico-
pathological parameters were evaluated using the c2 test. A proba-
bility < 0.05 was considered significant.
RESULTS
MN/G250 expression in RCC specimens
mAbG250 stained 128 of 147 (87.1%) cases, most demonstrating
homogeneous and strong binding. The staining strength and
percentages of positive tumour cells correlated in different areas of
the same RCC, in accordance with the results of our previous
study. Data for relations between MN/CA IX/G250 expression and
tumour stage and grade are summarized in Table 1. Significant
inverse links were noted in both cases P < 0.005 and P < 0.0001
respectively, i.e. high-grade tumours expressed MN/CA IX/G250
antigen at a significantly lower rate (33.3%) than low-grade
tumours (98.6%). MN/CA IX/G250 expression of tumour cells
was not related to the morphological type of RCC (Tables 2 and 3),
i.e. both clear cell and non-clear cell types expressed MN/CA
IX/G250. However, the proportion of clear cell tumours (95/96,
99.0%) homogeneously stained was greater than for the non-clear
cell type (33/51, 64.7%). RT-PCR analyses of RCC frozen speci-
mens resulted in clear detection of MN/CA9/G250 mRNA signals
(137/147, 93.2%) (Figure 1). However, the results were not iden-
tical to those of immunohistochemical analysis (Tables 2 and 3).
All positive stained tumours with mAbG250 expressed
MN/CA9/G250 mRNA by RT-PCR, but not vice versa, i.e. nine
tumours expressed MN/CA9/G250 mRNA by RT-PCR but did not
demonstrate MN/CA IX/G250 protein on immunohistochemistry.
MN/G250 expression in RCC cell lines
In eight of 17 RCC cell lines (47.0%), MN/CA9/G250 mRNA
signals were observed by RT-PCR analysis (Figure 2), and of these
eight RT-PCR(+) cell lines, only five expressed MN/CA IX/G250
antigen by MHA (Table 4). All MHA-positive cell lines (SKRC-6,
10, 38, 44, 52) expressed MN/CA9 mRNA, but not vice versa.
Detection of circulating MN/CA9/G250-positive cells in
the blood
RT-PCR sensitivity assay revealed that one single MN/CA9/G250-
positive cell in 1 ml whole blood was detectable (Figure 3).
Standard RT-PCR analysis (30 cycles) revealed the presence of
circulating MN/CA9/G250-positive cells in several blood samples
taken from inferior vena cava or renal vein during radical nephrec-
tomies, but not in peripheral blood samples (data not shown). To
obtain high sensitivity for detecting MN/CA9/G250-positive circu-
lating cells, nested PCR as well as PCR Southern blotting analyses
were carried out (Figure 4). Thereby, 76.2% (32/42) of blood
samples from RCC patients demonstrated MN/CA9/G250 mRNA,
although this was also the case for 32.2% (10/31) of the blood
samples from healthy donors without any disease (Table 5 and
Figure 4). The presence of MN/CA9/G250-expressing cells in
control blood was confirmed by the sequence analysis (data not
shown).
DISCUSSION
RCC is relatively resistant to conventional anticancer treatment such
as radiation, chemotherapy or hormonal therapy, and radical opera-
tions are considered the only way to achieve cures. However, it also
has a unique biological profile, demonstrating long dormancy of
metastasis and spontaneous regression after nephrectomy, and an
investigation concerning immune status of patients with RCCs
revealed that the biological behaviour of tumours was influenced by
host factors (Ritchie et al, 1987). So far, immunotherapy seems to be
the most promising treatment approach and cytokine immunotherapy
for RCC, e.g. with interferons and interleukin-2, has worldwide
MN/CA IX/G250 in renal cell carcinomas 743
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Figure 2 Results of RT-PCR analysis of MN/CA9 in RCC cell lines.
Seventeen RCC cell lines, SKRC-1, 6, 10, 12, 14, 17, 29, 33, 38, 39, 42, 44,
45, 52, 59, ACHN and YCR-1 were analysed by the RT-PCR method. G250
cDNA was used as a positive control. Representative results are shown
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Table 1 MN/G250 expression with respect to tumour stage and grade
Stage Total
T1 T2 T3 T4
MN/G250+ 25 68 32 3 128 (87.1%)
P < 0.005
MN/G250– 2 3 10 4 19 (12.9%)
Grade Total
G1 G2 G3
MN/G250+ 69 54 5 128 (87.1%)
P < 0.0001
MN/G250– 1 8 10 19 (12.9%)become the most common first therapeutic alternative next to
nephrectomy. Nevertheless, the prognosis of RCC patients with
disseminated disease is still extremely poor, and a more specific ther-
apeutic approach is needed. We have focused on the G250 antigen
expressed on a large proportion of RCCs as a promising target mole-
cule. Isolation and sequential analysis revealed G250 to be identical
to MN/CA IX (Oosterwijk et al, 1996), a N-glycosylated protein
originally identified in HeLa cells by mAb M75 (Pastoreková et al,
1992) and distributed on the plasma membrane as well as in the
nucleus. Immunohistochemical studies with mAb M75 as well as
mAbG250 for MN/CA IX/G250 expression have been carried out in
several malignancies. In RCC, the first immunohistochemical study
of MN/CA IX/G250 was reported by Oosterwijk et al (1986) using
mAbG250. However, it was not considered that both mAb M75 and
mAbG250 recognized the same antigen MN/CA IX/G250. Another
report by Liao et al (1997) using mAb M75 demonstrated very
similar results, i.e. 45 of 47 primary RCC (95%) were MN/CA
IX/G250-positive, all clear cell tumours with or without
granular/spindle cell expressing MN/CA IX/G250. Our extensive
study with mAbG250 revealed an inverse correlation between
MN/CA IX/G250 expression and tumour stage and grade, as
described in other diseases (Brewer et al, 1996; Turner et al, 1997;
Saarnio et al, 1998). Brewer et al (1996) have shown that low expres-
sion of MN/CA IX/G250 correlates with poor prognostic factors,
e.g. poorly differentiated tumour, lymph node metastasis, depth of
cervical stromal invasion, suggesting low MN/CA IX/G250 expres-
sion in tumour cells with higher malignant potential. Similar results
have been reported in colorectal cancer (Saarnio et al, 1998) and
oesophageal cancer (Turner et al, 1997). After cloning of MN/CA9
gene, this gene expression of benign human tissues and RCC was
investigated by RT-PCR assay using an oligonucleotide primer
specific for MN/CA9/G250 cDNA (McKiernan et al, 1997). In this
RT-PCR study of 17 RCC cases, 12 pure clear cell type tumours
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Table 2 MN/CA9/G250 expression with respect to cell type
Positive cases (%)
No. of cases mAbG250 (%) RT-PCR (%)
Clear cell 96 95 (99.0) 96 (100)
Granular cell 29 19 (65.5) 23 (79.3)
Mixed cell 17 13 (76.5) 17 (100)
Spindle cell 2 0 (0.0) 0 (0.0)
Pleomorphic cell 3 1 (33.3) 1 (33.3)
147 128 (87.1) 137 (93.2)
Table 3 MN/CA9/G250 expression with respect to growth pattern
Positive cases (%)
No. of cases mAbG250 (%) RT-PCR (%)
Alveolar 106 101 (95.3) 105 (99.1)
Tubular 17 16 (94.1) 16 (94.1)
Papillary 7 3 (42.9) 4 (57.1)
Cystic 5 3 (60.0) 3 (60.0)
Solid 7 1 (14.3) 4 (57.2)
Mixed 5 4 (80.0) 5 (100)
147 128 (87.1) 137 (93.2)
Table 4 MN/G250 expression in RCC cell lines
Cell line RT-PCR MHA
SKRC –1 + –
–6 + +
–10 + +
–12 – –
–14 – –
–17 – –
–29 – –
–33 – –
–38 + +
–39 – –
–42 – –
–44 + +
–45 – –
–52 + +
–59 + –
ACHN – –
YCR-1 + –
Table 5 Detection of circulating MN/G250-positive cell
MN/G250+ MN/G250– Total
RCC 33 (76.7%) 10 (23.3%) 43
Normal 10 (32.3%) 21 (67.7%) 31
PCR Southern
RT-PCR
495 bp
b-actin
275 bp
MN+ cells ml
–1 blood 01 0 0 101 102 103 104 105
RCC patients
Healthy
SKRC–44
123456789 1 0
Figure 3 Sensitivity assay of RT-PCR and PCR Southern blot. Different
dilutions of SKRC-44 (MN/CA IX/G250-positive) cell suspensions were
added to 10 ml aliquots of normal whole blood. Until at concentration of one
SKRC-44 cell in 1 ml whole blood, the mRNA signal can be detectable
Figure 4 MN/CA9 expression in blood samples, as analysed by PCR
Southern blotting. Blood samples from 43 RCC patients as well as 31 healthy
volunteers were investigated. RNA obtained from the SKRC-44 RCC cell line
was used as a positive control. Representative results are shownshowed MN/CA9/G250 expression and no expression was observed
in the remaining five granular or papillary cell type tumours with or
without clear cell elements. Although the first report by Oosterwijk et
al (1996) emphasized that reactivity with mAbG250 is not related to
morphological appearance of the cells, the two current reports
suggest that MN/CA IX/G250 may be cell-specific tumour-associ-
ated protein, i.e. a useful potential marker for clear cell type RCC.
Based on our results, a majority of RCC are MN/CA IX/G250-
positive; mAbG250(+)/RT-PCR(+) in 128 (87.1%), mAbG250(–)/
RT-PCR(+) in nine (6.1%) and mAbG250(–)/RT-PCR(–) in ten
cases (6.8%), respectively, with RT-PCR being a most reliable
detection method. It seems that MN/CA IX/G250 expression is
related to the clear cell type, with alveolar or tubular structures.
However, some non-clear cell type tumours with or without clear
cell elements were also MN/CA IX/G250-positive. Immuno-
histochemical and RT-PCR analyses for these groups were consis-
tent, so they may be indicated for immunotherapy. With the others,
where the RT-PCR approach was more sensitive, diagnostic appli-
cations may still be expected. Despite the fact that the standard RT-
PCR (30 cycles) resulted in clear detection of MN/CA9/G250
mRNA, nine RCC specimens and two cell lines did not show
MN/CA IX/G250 antigen expression. This discrepancy may be
due to lower sensitivity of immunohistochemical analysis. With
respect to the clinical usefulness of MN/CA IX/G250 antigen as a
target molecule, 19 (12.9%) of the mAbG250(–) cases might be
categorized as negative.
To further investigate whether MN/CA9/G250 could be a poten-
tial diagnostic marker, the RT-PCR assay was used to detect circu-
lating MN/CA9/G250-positive cells in blood from RCC patients.
Approximately three-quarters of the blood samples showed clear
expression of MN/CA9/G250 mRNA, whereas only one-third of
healthy donor samples were positive. Sequence analysis confirmed
the presence of circulating MN/CA9/G250-positive cells in the
control blood. With regard to the question of where these
MN/CA9/G250 antigen-positive cells come from, we are currently
investigating a variety of normal tissues including haematogenous
organs and haematopoietic cell lines, but so far, no clear expression
of MN/CA9/G250 has been observed except in the alimentary tract
(data not shown). McKiernan et al checked MN/CA9 expression of
several normal tissues including normal peripheral blood samples by
RT-PCR with different primers and showed no expression in any
normal samples (McKiernan et al, 1997). However, they subse-
quently also found MN/CA9/G250-expressing cells in normal blood
samples (McKiernan et al, 1998). This was confirmed by our
RT-PCR analysis with the same primers and conditions as they
employed (data not shown). Similar results have been reported for
other malignancies. For example, wide ranges of antigen detection
rates of circulating prostatic-specific antigen (PSA) or prostatic-
specific membrane antigen (PSM) positive cells in prostate cancer
cases have also been described (Hamdy et al, 1992; Sokoloff et al,
1996; Ignatoff et al, 1997). With the RT-PCR analyses of
MacKiernan and ourselves, hypersensitive RT-PCR assays with
PCR Southern blots or nested RT-PCR (total 50 cycles), allowed
detection of MN/CA9/G250-expressing cells in peripheral blood
samples. To confirm whether circulating MN/CA9/G250-positive
cells could be real RCC cells, further investigation with additional
markers is required. Unfortunately, there is no reliable marker
specific for RCC detection presently available. Since normal
alimentary tissues express MN/CA IX/G250, further precise study
with other normal tissues including haematological cells, is needed
to investigate the possible significance of MN/CA IX/G250-positive
cells in normal blood samples. However, because of the significantly
high detection rate in RCC, quantitative analysis of MN/CA9/G250
expression might allow discrimination from non-RCC. In order to
obtain both high sensitivity and specificity for detection of circu-
lating MN/CA9/G250-positive cells, optimal settings of RT-PCR are
under investigation.
In conclusion, our investigation of both MN/CA IX/G250 and
MN/CA9/G250 gene expression in a large number of RCC speci-
mens revealed the majority to express MN/CA IX/G250.
Immunohistochemical findings with mAbG250 (128/147, 87.1%)
was almost identical to the results of RT-PCR analysis (137/147,
93.2%). We also showed that RT-PCR analysis of blood samples
from RCC patients can detect circulating MN/CA9/G250-positive
cells, although the sensitivity (32/42, 76.2%) and specificity
(21/31, 77.8%) were relatively low. Our findings suggest that the
MN/CA9/G250 antigen is a promising tool as a therapeutic target
and a diagnostic marker for detection of residual disease after RCC
resection.
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